Sight Sciences (SGHT) Morgan Stanley 24th Annual Global Healthcare Conference summary

Business overview and recent evolution

• Focuses on interventional solutions for glaucoma and dry eye disease, with two commercial-stage technologies: OMNI for micro-invasive glaucoma surgery and TearCare for dry eye treatment.

• Both OMNI and TearCare businesses are now in growth mode, with OMNI regaining momentum and TearCare expanding rapidly after securing payer coverage.

• Over the past year, the company transitioned from a single-product focus to a diversified platform with strong growth in both segments.

• TearCare has nearly doubled revenue each quarter since reimbursement began, with ongoing efforts to expand payer coverage and market access.

• Growth is supported by hiring, provider training, and deepening coverage in key regions.

Financial performance and growth drivers

• Achieved 13% revenue growth in Q1 and 20% in Q2, driven by record account numbers and strong utilization in both businesses.

• Raised guidance for the year, citing robust underlying business metrics and market expansion.

• Standalone glaucoma procedures are accelerating, now representing a growing share of revenue mix (estimated at 20–25%).

• OMNI Ultra, a next-generation device, is being trialed and will launch broadly at the AAO meeting, expected to enhance procedural efficiency.

• TearCare sales reached over 3,000 lids and $2.7 million in revenue last quarter, nearly doubling sequentially.

Market development and strategic initiatives

• Standalone glaucoma interventions are a significant opportunity, targeting a large patient population not associated with cataract surgery.

• Efforts focus on activating office workflows to identify and consult glaucoma patients for intervention, mirroring cataract consultation processes.

• TearCare's growth is driven by expanded Medicare coverage, with a long-term goal to secure broader commercial payer access.

• Recent expanded label for TearCare validates its use for MGD treatment, supporting payer discussions and market adoption.

• Synergies between glaucoma and dry eye businesses leverage shared customer bases and workflow integration.